Compare RES & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RES | DAWN |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | N/A | 2021 |
| Metric | RES | DAWN |
|---|---|---|
| Price | $6.51 | $12.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $5.44 | ★ $27.56 |
| AVG Volume (30 Days) | 1.8M | ★ 2.6M |
| Earning Date | 02-03-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $1,536,150,000.00 | $133,672,000.00 |
| Revenue This Year | $16.18 | $17.32 |
| Revenue Next Year | $3.71 | $53.42 |
| P/E Ratio | $29.93 | ★ N/A |
| Revenue Growth | 4.20 | ★ 31.11 |
| 52 Week Low | $4.10 | $5.64 |
| 52 Week High | $7.04 | $13.53 |
| Indicator | RES | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 70.36 | 63.83 |
| Support Level | $6.05 | $9.84 |
| Resistance Level | $6.33 | $13.20 |
| Average True Range (ATR) | 0.22 | 0.98 |
| MACD | 0.06 | 0.24 |
| Stochastic Oscillator | 74.27 | 74.74 |
RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. The company's operating segment includes Technical Services and Support Services. It generates maximum revenue from the Technical Services segment. Technical Services segment nclude RPC's oil and gas services that utilize people and equipment to perform value-added completion, production and maintenance services directly to a customer's well. Support Services segment consists of drill pipe and related tools, pipe handling, pipe inspection and storage services, and oilfield training and consulting services.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.